Major Day for Artificial Pancreas Advancement
JDRF-Funded Researchers Report Success with First Automated Real-World Study in Type 1 Diabetes Patients
NEW YORK, October 28, 2011 – Pivotal advances toward the development of an artificial pancreas were announced today, furthering the prospect of bringing this innovative and life-saving device to market.
For the first time ever, patients were able to control their diabetes using an artificial pancreas system in a real-life setting, JDRF-funded researchers in Europe announced today at a press conference in Montpellier, France. The study took place in France and Italy. JDRF applauds this major step forward in the field of artificial pancreas research and in diabetes care because of how this work could transform the lives of millions of people with type 1 diabetes (T1D).
In parallel experiments performed at Montpellier University Hospital in France (led by professor Eric Renard and professor Jacques Bringer), and at the Universities of Padova and Pavia in Italy (led by Drs. Claudio Cobelli and Daniela Bruttomesso), two patients with T1D attained near-normal glucose levels after spending one night outside of a hospital while their diabetes was automatically managed by a prototype artificial pancreas system. The patients were able to eat a meal at a restaurant and spend one night at a hotel while using the device.
“This marks a day that has been long awaited by people with type 1 diabetes, and we congratulate the researchers for this important achievement,” said Jeffrey Brewer, president and CEO of JDRF. “We are now bounds closer to the realization of the first generation of an artificial pancreas that will truly revolutionize diabetes care.”
Read the full press release and the article “JDRF Applauds Medtronic on FDA Approval of Low-Glucose Suspend Device Trial”.
To learn more about the JDRF Dallas chapter, visit our JDRF Dallas website!